THE

FASTER

WE MOVE

MEDSIR ATTENDS MANY GLOBAL SCIENTIFIC CONGRESSES THROUGHOUT THE YEAR. WE LOOK FORWARD TO MEETING YOU!

MEDSIR ATTENDS MANY GLOBAL SCIENTIFIC CONGRESSES THROUGHOUT THE YEAR. WE LOOK FORWARD TO MEETING YOU!

PHENOMENAL Study reach a New Milestone!

This last September (2019), the 23rd patient in the Phenomenal Study was included in the trial. We have reached a new milestone, the Stage I have recruited 23 evaluable patients. An interim analysis...

December 19, 2019

A New Trial On Board: The ORPHEUS Study

MedSIR will soon begin the ORPHEUS study “A Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of INCMGA00012 in Advanced Penile Squamous...

December 2, 2019

REVERT Study Poster Presentation at SABCS 2019

REVERT study (design, background, primary, a secondary endpoint, trial enrollment) has been scheduled for presentation in a Poster Session at SABCS 2019 on San Antonio (Texas, USA)...

December 13, 2019

Last Patient Last Visit for Interim Analysis in PHERGain Study

A new milestone of PHERGain study-Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer: FDG-PET response-adapted strategy-has been achieved...

November 21, 2019

The Beginning of the LUZERN Study

Last 11th November 2019, it was submitted the LUZERN study to AEMPS and CEIm with the participation of 10 different sites in Spain. Overall, we expect to recruit a total of 23 patients. Sites activation is...

December 5, 2019

Liquid biopsy and ctDNA: the winner tandem

Precision medicine is an approach to patient care that allows doctors to select treatments that are most likely to help patients based on a genetic understanding of their disease. Recent advances in science...

November 13, 2019